We are grateful to all the participants that enrolled in the present study for their consent and cooperation, and Medicines for Malaria Venture (MMV) for permitting the study during the implementation of treatment with tafenoquine and the G6PD test in Porto Velho, RO, Brazil. We also thank Fiocruz Rond√¥nia for all the support during the study. Under the grant conditions of the foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the author-accepted manuscript version that might arise from this submission.